Thermo Fisher Scientific Inc. entered into a definitive agreement to acquire CorEvitas, a provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity, for $912.5 million in cash. CorEvitas will become part of Thermo Fisher’s Laboratory Products and Biopharma Services segment. The transaction is expected to be completed by the end of 2023. CorEvitas, with operations in the U.S., provides services to pharmaceutical and biot...